Next Article in Journal
An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis
Previous Article in Journal
A 3-miRNA Signature Enables Risk Stratification in Glioblastoma Multiforme Patients with Different Clinical Outcomes
Previous Article in Special Issue
Living-Donor Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Score and Predictive Value of NLR on Survival
Article

Outcomes of Geriatric Patients with Hepatocellular Carcinoma

1
Division of General Internal Medicine and Geriatrics, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan
2
Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan
3
College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
4
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(6), 4332-4341; https://doi.org/10.3390/curroncol29060346
Received: 7 May 2022 / Revised: 12 June 2022 / Accepted: 14 June 2022 / Published: 16 June 2022
Background: The treatment modalities and outcomes of geriatric patients with hepatocellular carcinoma (HCC) remain controversial. This retrospective observational cohort study compared the outcomes of HCC between geriatric and younger patients. Methods: The medical records of patients with HCC managed between January 2001 and December 2017 were retrieved from the Chang Gung Memorial Hospital Research Database. Patients were stratified by age into two groups: a geriatric group (65–75 years) and a younger group (<65 years). The two groups were matched through 1:2 propensity score matching (PSM) according to sex, cardiovascular disease, cerebrovascular attack, diabetes mellitus, cirrhosis, hepatitis, and hypertension. Results: Of the 11,033 patients with HCC, 2147 patients aged 65–75 years and 4294 patients aged <65 years were identified after 1:2 PSM. The Kaplan–Meier model revealed that the HCC outcomes in patients older than 65 years were not significantly different after 3 years (p = 0.060). Consistent results were also obtained when the laboratory data associated with HCC incidence were included in the Fine–Gray competing risk model after 1:2 PSM (p = 0.1695). The major risk factors for HCC survival were systemic immune-inflammation index (SII) ≥ 610 × 109 cells/L, advanced tumor stage, and model for end-stage liver disease (MELD) score, etc. Conclusion: Age was not an independent factor for mortality in patients with HCC in the first 3 years. Geriatric patients with HCC should be as aggressively managed as younger patients. View Full-Text
Keywords: hepatocellular carcinoma; geriatric patients; mortality hepatocellular carcinoma; geriatric patients; mortality
Show Figures

Figure 1

MDPI and ACS Style

Lee, C.-H.; Yen, T.-H.; Hsieh, S.-Y. Outcomes of Geriatric Patients with Hepatocellular Carcinoma. Curr. Oncol. 2022, 29, 4332-4341. https://doi.org/10.3390/curroncol29060346

AMA Style

Lee C-H, Yen T-H, Hsieh S-Y. Outcomes of Geriatric Patients with Hepatocellular Carcinoma. Current Oncology. 2022; 29(6):4332-4341. https://doi.org/10.3390/curroncol29060346

Chicago/Turabian Style

Lee, Chern-Horng, Tzung-Hai Yen, and Sen-Yung Hsieh. 2022. "Outcomes of Geriatric Patients with Hepatocellular Carcinoma" Current Oncology 29, no. 6: 4332-4341. https://doi.org/10.3390/curroncol29060346

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop